We are live on ! Find out more
VXRT

Vaxart

Delisted

VXRT was delisted on the 7th of July, 2025.

109 hedge funds and large institutions have $25.8M invested in Vaxart in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 36 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

353% more call options, than puts

Call options by funds: $204K | Put options by funds: $45K

8.63% less ownership

Funds ownership: 33.76%25.13% (-8.6%)

17% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 36

17% less funds holding

Funds holding: 132109 (-23)

40% less capital invested

Capital invested by funds: $42.9M → $25.8M (-$17.2M)

72% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 29

Holders
109
Holders Change
-23
Holders Change %
-17.42%
% of All Funds
1.74%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
30
Reduced
36
Closed
29
Calls
$204K
Puts
$45K
Net Calls
+$159K
Net Calls Change
-$538K

VXRT Hedge Fund Activity: Q1 2023 in Review

109 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Vaxart (VXRT) for Q1 2023, worth a combined $25.8M — down 40% from $42.9M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of VXRT and 8 opened new positions — a net loss of 21 holders — while 36 trimmed existing stakes and 30 added.

The largest buyer was Nuveen, adding an estimated $1.12M. The largest seller was Citadel Advisors, cutting an estimated $1.82M.

  • 109 institutional investors held Vaxart (VXRT) as of Q1 2023, down from 132 in Q4 2022.
  • Funds reported $25.8M of Vaxart stock for Q1 2023, down 40% quarter-over-quarter.
  • 8 funds opened new Vaxart positions in Q1 2023 and 29 closed out, a net change of -21 holders.
  • The largest Vaxart buyer in Q1 2023 was Nuveen, an estimated $1.12M added.
  • The largest Vaxart seller in Q1 2023 was Citadel Advisors, an estimated $1.82M sold.

Based on aggregated 13F filings for Q1 2023.